Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Matthew Gline is a director nominee for Arbutus Biopharma Corporation.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Roivant Sciences Ltd.

2021-01-01 · current

Confirmed by public sourceView source

Director

Arbutus Biopharma Corp

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Arbutus Biopharma Corp

Open Arbutus Biopharma Corp profile →

Director at Arbutus Biopharma Corp

Start not stated → End not stated

current · source reported

Observed: 2026-09-25

Arbutus Biopharma …Arbutus Biopharma CorpRoivant Sciences L…Roivant Sciences Ltd.Matthew Gline

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingABUS DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 2 · Sec FilingRoivant Sciences director board sourceSupports Board membership, Director since, Board independence.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:matthew-gline-2
Record version
public-0

Published evidence records

10 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ABUS DEF 14A executive officers

    sec filing · Source published: Apr 14, 2026 · Retrieved: May 14, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Arbutus Biopharma Corp · Claim reviewed: May 14, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 14, 2026
    • Other Company Role: Matthew Gline is also linked to Roivant Sciences as Chief Executive Officer. · Claim reviewed: May 14, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 14, 2026

  2. ABUS DEF 14A director slate

    sec filing · Source published: Apr 14, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  3. Open source

    sec proxy · Source published: Apr 14, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Arbutus Biopharma Corp · Claim reviewed: May 15, 2026

  4. Roivant Sciences director board source

    sec filing · Source published: Jul 29, 2025 · Retrieved: May 3, 2026

    Supports 3 claims
    • Board independence: Not independent (executive director) · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Arbutus Biopharma Corp · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Roivant Sciences · Claim reviewed: May 3, 2026

  5. ROIV DEF 14A director slate

    sec filing · Source published: Jul 29, 2025 · Retrieved: May 6, 2026

    Supports 4 claims
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Roivant Sciences · Claim reviewed: May 6, 2026
    • Executive title: Executive title: Chief Executive Officer · Claim reviewed: May 6, 2026

  6. ROIV DEF 14A executive officers

    sec filing · Source published: Jul 29, 2025 · Retrieved: May 6, 2026

    Supports 2 claims
    • Executive company: Executive at Roivant Sciences · Claim reviewed: May 6, 2026
    • Executive title: Executive title: Chief Executive Officer and Director · Claim reviewed: May 6, 2026

  7. Open source

    sec proxy · Source published: Jul 29, 2025 · Retrieved: Apr 29, 2026

    Supports 1 claim
    • Professional Role: Director at Roivant Sciences Ltd. · Claim reviewed: May 15, 2026

  8. ROIV executive roster source

    sec filing · Source published: Date unavailable · Retrieved: May 3, 2026

    Supports 5 claims
    • AI expertise: AI expertise: not identified in the cited filing · Claim reviewed: May 3, 2026
    • AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
    • Executive company: Executive at Roivant Sciences · Claim reviewed: May 6, 2026
    • Executive function: Enterprise Leadership (CEO) · Claim reviewed: May 3, 2026
    • Executive title: Executive title: Chief Executive Officer and Director · Claim reviewed: May 6, 2026

  9. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Roivant Sciences · Claim reviewed: May 3, 2026

  10. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Arbutus Biopharma Corp · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

AI expertise · Source reportedAI expertise: not identified in the cited filing1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

AI governance relevance · Source reportedAI governance relevance reported from role and filings1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board independence · Source reportedNot independent (executive director)1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Arbutus Biopharma CorpSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board membership · CorroboratedServes on the board of Roivant SciencesSupported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · CorroboratedBoard role: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Committee assignments · CorroboratedNo committee assignment disclosed in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Arbutus Biopharma Corp1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Executive company · CorroboratedExecutive at Roivant SciencesSupported by 3 public records3 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive function · Source reportedEnterprise Leadership (CEO)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · Source reportedExecutive title: Chief Executive Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Executive title · CorroboratedExecutive title: Chief Executive Officer and DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Other Company Role · Source reportedMatthew Gline is also linked to Roivant Sciences as Chief Executive Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Technology background · Under reviewTechnology background: not identified in the cited filing1 source
Verification
Under review
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Under reviewTechnology background reported in filings1 source
Verification
Under review
Confidence
72%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

View all sources10 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  3. https://www.sec.gov/Archives/edgar/data/1447028/000114036126014623/ny20065142x1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Arbutus Biopharma Corp (NASDAQ: ABUS)

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Director since · Board independence

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

    Supports: Board role · Committee assignments · Executive company · Executive title

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

    Supports: Executive company · Executive title

  7. https://www.sec.gov/Archives/edgar/data/1635088/000114036125027846/ny20049997x1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 29, 2026

    Supports: Director at Roivant Sciences Ltd. (NASDAQ: ROIV)

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: AI expertise · AI governance relevance · Executive company · Executive function · Executive title

  9. https://www.sec.gov/Archives/edgar/data/1635088/000114036125027846/ny20049997x1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/1447028/000114036126014623/ny20065142x1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership